Gardner A. Mark's most recent trade in Quest Diagnostics, Inc. was a trade of 120 Common Stock done at an average price of $155.7 . Disclosure was reported to the exchange on Sept. 24, 2024.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Quest Diagnostics, Inc. | Mark A. Gardner | SVP of Molecular Gen & Oncol | 24 Sep 2024 | 120 | 4,673 (0%) | 0% | 155.7 | 18,684 | Common Stock | |
| Quest Diagnostics, Inc. | Mark A. Gardner | SVP of Molecular Gen & Oncol | 28 Feb 2024 | 262 | 4,793 (0%) | 0% | 126.4 | 33,106 | Common Stock | |
| Quest Diagnostics, Inc. | Gardner A. Mark | SVP of Molecular Gen & Oncol | 14 Feb 2024 | 9,376 | 9,376 | - | - | Non-Qualifed Stock Option (right to buy) | ||
| Quest Diagnostics, Inc. | A. Mark Gardner | SVP of Molecular Gen & Oncol | 14 Feb 2024 | 2,250 | 5,055 (0%) | 0% | 0 | Common Stock | ||
| Quest Diagnostics, Inc. | Mark A. Gardner | SVP of Molecular Gen & Oncol | 25 Sep 2023 | 116 | 2,805 (0%) | 0% | 126.2 | 14,642 | Common Stock | |
| Quest Diagnostics, Inc. | Mark A. Gardner | SVP of Molecular Gen & Oncol | 23 Feb 2023 | 7,584 | 7,584 | - | - | Non-Qualifed Stock Option (right to buy) | ||
| Quest Diagnostics, Inc. | Mark A. Gardner | SVP of Molecular Gen & Oncol | 23 Feb 2023 | 1,919 | 2,921 (0%) | 0% | 0 | Common Stock |